Comparative Pharmacology
Head-to-head clinical analysis: ACCUPRIL versus AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCUPRIL versus AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE.
ACCUPRIL vs AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits ACE, thereby blocking conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing peripheral vasodilation and reduction of peripheral vascular resistance. Benazepril is a prodrug that is hydrolyzed to benazeprilat, a competitive inhibitor of angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction, aldosterone secretion, and sodium and water retention.
10-40 mg orally once daily; initial dose 10 mg, titrate to target dose based on blood pressure response; maximum 80 mg/day.
Oral, one capsule daily. Initial: 2.5 mg/10 mg for patients not on either drug; up to 10 mg/40 mg daily.
None Documented
None Documented
Quinaprilat terminal elimination half-life is approximately 3 hours. In patients with renal impairment (CrCl <30 mL/min), half-life can be prolonged up to 10-25 hours, requiring dose adjustment.
Amlodipine terminal half-life 30-50 hours (allows once-daily dosing; steady state reached after 7-10 days). Benazeprilat effective half-life 10-11 hours (accumulation minimal).
Primarily renal (about 60% as unchanged drug and 40% as metabolites, mainly quinaprilat), with biliary/fecal elimination accounting for less than 10%.
Amlodipine: 60% renal (10% unchanged, rest as metabolites), 20-25% biliary/feces. Benazepril: 11-12% renal (as unchanged benazepril and benazeprilat), 85-90% biliary (as benazeprilat conjugates).
Category C
Category D/X
ACE Inhibitor
ACE Inhibitor